6/12
10:02 pm
tcon
TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Low
Report
TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
6/11
08:13 am
tcon
TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients [Yahoo! Finance]
Medium
Report
TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients [Yahoo! Finance]
6/11
08:00 am
tcon
TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients
High
Report
TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients
5/18
03:38 am
tcon
TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Low
Report
TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
5/14
04:16 pm
tcon
TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
High
Report
TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
5/14
04:01 pm
tcon
TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
High
Report
TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
5/11
12:15 am
tcon
TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Medium
Report
TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
5/7
04:01 pm
tcon
TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024
Medium
Report
TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024
4/16
02:08 am
tcon
TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) is now covered by analysts at StockNews.com. They set a "strong-buy" rating on the stock.
Medium
Report
TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) is now covered by analysts at StockNews.com. They set a "strong-buy" rating on the stock.
4/8
09:10 am
tcon
TRACON Pharmaceuticals Announces Reverse Stock Split
High
Report
TRACON Pharmaceuticals Announces Reverse Stock Split
4/8
02:07 am
tcon
TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) is now covered by analysts at StockNews.com. They set a "strong-buy" rating on the stock.
High
Report
TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) is now covered by analysts at StockNews.com. They set a "strong-buy" rating on the stock.
4/3
01:14 pm
tcon
TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) had its price target lowered by analysts at HC Wainwright from $6.00 to $3.00. They now have a "buy" rating on the stock.
High
Report
TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) had its price target lowered by analysts at HC Wainwright from $6.00 to $3.00. They now have a "buy" rating on the stock.
4/3
08:24 am
tcon
TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned [Yahoo! Finance]
High
Report
TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned [Yahoo! Finance]
4/3
08:00 am
tcon
TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned
High
Report
TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned
3/31
02:09 am
tcon
TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) is now covered by analysts at StockNews.com. They set a "strong-buy" rating on the stock.
Medium
Report
TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) is now covered by analysts at StockNews.com. They set a "strong-buy" rating on the stock.
3/28
10:58 pm
tcon
Alphamab Oncology Reports Full Year 2023 Financial Results and Business Highlights [Yahoo! Finance]
Medium
Report
Alphamab Oncology Reports Full Year 2023 Financial Results and Business Highlights [Yahoo! Finance]
3/23
02:10 am
tcon
TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) is now covered by analysts at StockNews.com. They set a "strong-buy" rating on the stock.
Low
Report
TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) is now covered by analysts at StockNews.com. They set a "strong-buy" rating on the stock.